Kane Biotech (CVE:KNE) Shares Up 25% – Time to Buy?

Kane Biotech Inc. (CVE:KNE)’s stock price was up 25% during mid-day trading on Wednesday . The stock traded as high as C$0.03 and last traded at C$0.03. Approximately 787,700 shares changed hands during mid-day trading, an increase of 339% from the average daily volume of 179,583 shares. The stock had previously closed at C$0.02.

Kane Biotech Price Performance

The firm has a 50-day moving average of C$0.03 and a two-hundred day moving average of C$0.03. The firm has a market cap of C$6.15 million, a price-to-earnings ratio of -3.00 and a beta of 1.05. The company has a current ratio of 0.45, a quick ratio of 0.39 and a debt-to-equity ratio of -135.17.

Kane Biotech Company Profile

Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand.